文献速递临床试验与 GCP基础与转化研究

生姜泻心汤预防小细胞肺癌化疗相关性腹泻的疗效与安全性:多中心随机对照试验方案

Efficacy and safety of Shengjiang Xiexin decoction in prophylaxis of chemotherapy-related diarrhea in small cell lung cancer patients: study protocol for a multicenter randomized controlled trial.
PubMed 文献 · Trials · 2020-05-01

本研究为前瞻性、双盲、随机、安慰剂对照试验,计划在中国五家医院纳入100例未接受过伊立替康治疗的小细胞肺癌患者,按UGT1A1基因型分层随机1:1分配至生姜泻心汤或安慰剂组,评价生姜泻心汤预防伊立替康所致腹泻的疗效与安全性。主要结局为腹泻发生率,次要结局包括腹泻程度、中性粒细胞减少程度、化疗方案更改率、止泻药用量、住院率及化疗疗效评价。

要点

  • 生姜泻心汤预防伊立替康所致腹泻的疗效与安全性尚需随机对照试验验证。
  • 按UGT1A1基因型分层随机,个体化评估腹泻风险。
  • 主要结局为腹泻发生率,次要结局涵盖腹泻程度及化疗相关指标。

核心结论

  • 该研究旨在评估生姜泻心汤预防伊立替康所致腹泻的疗效与安全性,结果尚未报告。

研究设计与样本

  • 前瞻性、双盲、随机、安慰剂对照试验,在中国五家医院开展。
  • 计划纳入100例未接受过伊立替康治疗的小细胞肺癌患者,按1:1随机分配至生姜泻心汤组或安慰剂组。
  • 采用分层随机,按UGT1A1基因型将受试者分为不同腹泻风险组。
  • 干预为两个化疗周期,每个周期化疗开始前3天至开始后11天口服生姜泻心汤或安慰剂。

关键数值与推荐

  • 主要结局为腹泻发生率。
  • 次要结局包括腹泻程度、中性粒细胞减少程度、化疗方案更改率、止泻药用量、住院率及化疗疗效评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diarrhea is a common adverse reaction in patients with cancer receiving chemotherapy, for which there is currently no effective method of treatment. Shengjiang Xiexin decoction (SXD), a classic traditional Chinese medicine (TCM) formula, has shown efficacy in alleviating irinotecan-induced diarrhea in preliminary clinical studies. The current study is designed to assess the efficacy and safety of SXD for prophylaxis against irinotecan-induced diarrhea. Additionally, we employ a new approach to analyze and evaluate the data based on the patients' uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotype, which predicts the risk of diarrhea. METHODS AND DESIGN: A prospective, double-blind, randomized, placebo-controlled trial will be conducted in patients with small cell lung cancer (SCLC) from five hospitals in China. For this study, 100 irinotecan-naïve patients will be randomly allocated to either the SXD or placebo arms in a 1:1 ratio. Stratified randomization will be used to divide subjects by UGT1A1 genotype into groups with differing risk of diarrhea. The trial will consist of two cycles of chemotherapy with 14 days of oral administration of SXD or placebo administered beginning between 3 days before and up to 11 days after initiation of each chemotherapy cycle. The primary study outcome is the incidence of diarrhea. Secondary outcomes include the degree of diarrhea, the degree of neutropenia, the rate of alterations in chemotherapy regimens, the amount of antidiarrheal drug taken, the rate of hospitalization, and evaluation of chemotherapy efficacy. DISCUSSION: This study is the first to use the UGT1A1 genotype to stratify patients into groups based on their risk of diarrhea, and to provide a complete assessment of chemotherapy-related diarrhea (CRD), including records of diarrhea duration, grading the severity of diarrhea, and evaluating concomitant symptoms. Study results will provide high-level clinical evidence on the use of SXD as prophylaxis for CRD. TRIAL REGISTRATION: Chinese Clinical Trial Register: ChiCTR1800018490. Registered on 20 September 2018. Retrospectively registered. http://www.chictr.org.cn/edit.aspx?pid=25250&htm=4c.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Deng C, Lou Y, Gao Y, et al. Efficacy and safety of Shengjiang Xiexin decoction in prophylaxis of chemotherapy-related diarrhea in small cell lung cancer patients: study protocol for a multicenter randomized controlled trial. Trials. 2020. PMID: 32357899. doi:10.1186/s13063-020-04275-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。